These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30715156)

  • 1. On the need to adjust for multiplicity in confirmatory clinical trials with master protocols.
    Stallard N; Todd S; Parashar D; Kimani PK; Renfro LA
    Ann Oncol; 2019 Apr; 30(4):506-509. PubMed ID: 30715156
    [No Abstract]   [Full Text] [Related]  

  • 2. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
    Tuma RS
    J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.
    Arteaga CL; Baselga J
    Clin Cancer Res; 2003 May; 9(5):1579-89. PubMed ID: 12738709
    [No Abstract]   [Full Text] [Related]  

  • 4. SOP 13: Pharmacokinetic data analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():56-9. PubMed ID: 23570190
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of nonrandomized trials in the evaluation of oncology drugs.
    Simon R; Blumenthal GM; Rothenberg ML; Sommer J; Roberts SA; Armstrong DK; LaVange LM; Pazdur R
    Clin Pharmacol Ther; 2015 May; 97(5):502-7. PubMed ID: 25676488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the evaluation of new cancer treatments: challenges and opportunities.
    Rothenberg ML; Carbone DP; Johnson DH
    Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erbitux trial flawed from the beginning, committee finds.
    Randal J
    J Natl Cancer Inst; 2002 Dec; 94(24):1824-5. PubMed ID: 12488469
    [No Abstract]   [Full Text] [Related]  

  • 8. Demystify statistical significance--time to move on from the p value to bayesian analysis.
    Lee JJ
    J Natl Cancer Inst; 2011 Jan; 103(1):2-3. PubMed ID: 21131578
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytotoxic drugs: the search for dose response.
    Dodwell DJ
    Lancet; 1993 Mar; 341(8845):614-6. PubMed ID: 8094841
    [No Abstract]   [Full Text] [Related]  

  • 10. Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study.
    Hobbs BP; Kane MJ; Hong DS; Landin R
    Ann Oncol; 2018 Dec; 29(12):2296-2301. PubMed ID: 30335125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of overviews in cancer therapeutics.
    Simon R
    Stat Med; 1987; 6(3):389-96. PubMed ID: 3616291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOP 09: Statistical design and analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
    [No Abstract]   [Full Text] [Related]  

  • 13. NCI's cancer therapy evaluation program: a commitment to treatment trials.
    Abrams JS; Murgo A; Christian MC
    Cancer Treat Res; 2007; 132():31-50. PubMed ID: 17305016
    [No Abstract]   [Full Text] [Related]  

  • 14. Ensuring trial conduct is consistent with trial design: assumption is the enemy of quality.
    Kelly J; Hounsome B; Lambert G; Murphy C
    Trials; 2019 Jul; 20(1):416. PubMed ID: 31291974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOP 03: Preparation and structure of trial protocols.
    Onkologie; 2003 Oct; 26 Suppl 6():11-4. PubMed ID: 23570179
    [No Abstract]   [Full Text] [Related]  

  • 16. Handling of Missing Data.
    Budhiraja P; Kaplan B; Mustafa RA
    Transplantation; 2020 Jan; 104(1):24-26. PubMed ID: 31365474
    [No Abstract]   [Full Text] [Related]  

  • 17. Qualitative and mixed methods research in trials.
    Snowdon C
    Trials; 2015 Dec; 16():558. PubMed ID: 26646545
    [No Abstract]   [Full Text] [Related]  

  • 18. Data submission standards and evidence requirements.
    Abrams J; Erwin R; Fyfe G; Schilsky RL
    Oncologist; 2010; 15(5):488-91. PubMed ID: 20489185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methodology for clinical trials in cancer patients with febrile neutropenia. Do we have a consensus?
    Feld R
    Support Care Cancer; 1998 Sep; 6(5):423-4. PubMed ID: 9773456
    [No Abstract]   [Full Text] [Related]  

  • 20. Statistical planning in confirmatory clinical trials with multiple treatment groups, multiple visits, and multiple endpoints.
    Sun H; Snyder E; Koch GG
    J Biopharm Stat; 2018; 28(1):189-211. PubMed ID: 28992425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.